Vertex casually drops Orkambi revenue slowdown, creating

Cystic fibrosis drugmaker Vertex this week informally backed away from its revenue guidance for key med Orkambi--and investors should be just as unhappy with execs’ conduct as they should be about | Cystic fibrosis drugmaker Vertex this week informally backed away from its revenue guidance for key med Orkambi--and investors should be just as unhappy with execs’ conduct as they should be about the revenue slip, one analyst says.

S-1

Vertex casually drops Orkambi revenue slowdown, creating 'unnecessary drama' for investors

Dropbox Business Model - How Dropbox Makes Money?

Vertex grows on back of Trikafta/Kaftrio sales

Vertex (VRTX) Beats on Q4 Earnings & Sales, '23 View Encouraging

SEC Filing – Royalty Pharma

Motley Fool: Smart shopping, how dumb is it to gamble and this week's trivia

SEC Filing – Royalty Pharma

SEC Filing – Royalty Pharma

SEC Filing – Royalty Pharma

Oracle Stock (ORCL) Jumps After Revenue Tops Estimates on Strong Cloud Effort - Bloomberg

Check out these new features and extensions kicked off at Google Summer of Code 2015